N-hydroxacylamino compounds, process for their preparation and pharmaceutical compositions containing them
AssigneeAstraZeneca AB
InventorsRebecca J Cartwright, Robert I Dowell
Life of this patent
Estimating the term…
Loading patent…
AssigneeAstraZeneca AB
InventorsRebecca J Cartwright, Robert I Dowell
Estimating the term…
A compound of the formula (I): R1—CO—N(OH)—CR2R3—CR4R5—CONH—CR6R7—CONR8R9 (I) wherein: R1 is C1-6alkyl, aryl or arylC1-6alkyl; R2 is hydrogen, C1-6alkyl, C3-8cycloalkyl, aryl or arylC1-6alkyl; R3 is hydrogen, C1-6alkyl or arylC1-6alkyl; or R2 and R3, together with the carbon atom to which they are joined, form a C3-8cycloalkyl ring; R4 is benzyl, phenethyl, phenylpropyl, phenylbutyl or flurophenylbutyl; R5 is hydrogen, C1-6alkyl or arylC1-6alkyl; R6 is hydrogen, C1-6alkyl, C2-6alkenyl, C3-8cycloalkylC1-6alkyl, arylC1-6alkyl, heteroarylC1-6alkyl or the side-chain of a naturally occurring amino acid; R7 is hydrogen or C1-6alkyl; R8 is hydrogen, C1-6alkyl, C3-8cycloalkyl, C3-8cycloalkenyl, arylC1-6alkyl, heteroarylC1-6alkyl or heterocyclylC1-6alkyl; R9 is hydrogen or C1-6alkyl; or R8 and R9, together with the nitrogen atom to which they are joined, form a heterocyclic ring; wherein any group or ring in R1-R9 is optionally substituted; or a pharmaceutically-acceptable salt or in vivo hydrolysable precursor thereof.
A compound of the formula (I):
A pharmaceutical composition which comprises a compound of the formula (I) or a pharmaceutically acceptable salt or an in vivo hydrolysable precursor and pharmaceutically acceptable carrier.
A pharmaceutical composition which comprises a compound of the formula (II) or a pharmaceutically acceptable salt or an in vivo hydrolysable precursor and pharmaceutically acceptable carrier.
A compound of the formula (I) or (II) or a pharmaceutically acceptable salt or in vivo hydrolysable precursor thereof for use in a method of therapeutic treatment of the human or animal body.
A method of treating a disease condition mediated by one or more metalloproteinase enzymes which comprises administering to a warm-blooded animal an effective amount of a compound of the formula (I) or (II) or a pharmaceutically acceptable salt or in vivo hydrolysable precursor thereof.
Dependencies are inferred from the claim text.